Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

BACKGROUND: Most cutaneous squamous cell carcinomas (CSCCs) can be treated with surgical excision or radiation; however, approximately 1% of patients develop advanced disease. In 2018, the FDA approved cemiplimab-rwlc as the first programmed cell death-1 (PD-1) monoclonal antibody for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Paul, Eleanor, Konidaris, Gerasimos, Cope, Shannon, Chen, Chieh-I, Keeping, Sam, Xu, Yingxin, Atsou, Kokuvi, Ayers, Dieter, Guyot, Patricia, Sasane, Medha, Mojebi, Ali, Kuznik, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394223/
https://www.ncbi.nlm.nih.gov/pubmed/34351214
http://dx.doi.org/10.18553/jmcp.2021.21164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394223/
https://www.ncbi.nlm.nih.gov/pubmed/34351214
http://dx.doi.org/10.18553/jmcp.2021.21164

Ejemplares similares